VYNE Therapeutics Inc
VYNE
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.36M
Close$
$0.48
27.3% downside
Current Fair Value
27.3% downsideOvervalued by 27.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.36 Million |
|---|---|
| Enterprise Value | $-13,267,205.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.62 |
| Beta | 2 |
| Outstanding Shares | 42,768,000 |
Return
| Return on Equity | -87.09% |
|---|---|
| Return on Assets | -82.93% |
| Return on Invested Capital | -95.36% |
Valuation & Multiples
| P/E Ratio | -1.36 |
|---|---|
| PEG | 2.33 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -29.22 |
| Enterprise Value to EBIT | 0.56 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$200,000
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.18
Average shareholder expectationRevenue Estimate
$200,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 30.77%▲ 11.63% |
|---|---|
| Total Invested | $7.86M▲ 65.72% |
| Investors Holding | 42▲ 3.00% |
ESG Score
No data
About VYNE Therapeutics Inc
106 employeesVYNE's mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.